DGX
Latest Trade
145.71USDChange
--(--)Today's Range
-
--52 Week Range
-
160.56As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 145.71 |
|---|---|
Open | -- |
Volume | -- |
3M AVG Volume | 26.11 |
Today's High | -- |
Today's Low | -- |
52 Week High | 160.56 |
52 Week Low | 113.36 |
Shares Out (MIL) | 130.64 |
Market Cap (MIL) | 17,559.82 |
Forward P/E | 12.06 |
Dividend (Yield %) | 1.73 |
Quest Diagnostics Says A Unit Of Co Experienced A Data Security Incident
Quest Diagnostics Updates Outlook For Full Year 2021
Quest Diagnostics Acquires Boca Raton-Based Nationwide Laboratory Services
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates under two segments: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services develops and delivers diagnostic testing information and services, providing insights that enables a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers, and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, and other brands, such as AmeriPath, Dermpath Diagnostics, ExamOne, Quanum. It also helps in delivering diagnostic insights for COVID-19 and a range of other medical conditions for communities in South Florida.
Industry
Healthcare Facilities
Contact Info
500 Plaza Dr
SECAUCUS, NJ
07094-3619
United States
+1.973.5202700
https://www.questdiagnostics.com/Executive Leadership
Stephen H. Rusckowski
Chairman of the Board, President, Chief Executive Officer
Mark J. Guinan
Chief Financial Officer, Executive Vice President
James E. Davis
Executive Vice President, General Diagnostics
Michael E. Prevoznik
Senior Vice President, General Counsel
Catherine T. Doherty
Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing
Price To Earnings (TTM) | 8.57 |
|---|---|
Price To Sales (TTM) | 1.59 |
Price To Book (MRQ) | 2.97 |
Price To Cash Flow (TTM) | 6.64 |
Total Debt To Equity (MRQ) | 67.98 |
LT Debt To Equity (MRQ) | 67.94 |
Return on Investment (TTM) | 20.31 |
Return on Equity (TTM) | 17.45 |
U.S. laboratory Quest Diagnostics Inc raised its full-year profit outlook on Thursday, saying it expects an uptick in COVID-19 testing demand due to the surge in infections from the Delta variant of the coronavirus.
Quest Diagnostics Inc raised its full-year profit outlook on Thursday, saying it expects an uptick in COVID-19 testing demand due to the surge in infections from the Delta variant of the coronavirus.
U.S. laboratory Quest Diagnostics Inc said on Thursday demand for COVID-19 testing had increased since the end of June as the more infectious Delta variant spreads across the country.
* QUEST DIAGNOSTICS EXECUTIVE SAYS IN RECENT WEEKS, HAVE SEEN COVID-19 PCR TESTING VOLUMES STABILIZE AND INCREASE MODESTLY: CONF CALL
Abbott Laboratories beat quarterly profit estimates on Thursday, driven by a rebound in its non-COVID-19 testing business and sales of its medical devices as vaccinations encouraged Americans to resume non-urgent procedures.
Major U.S. laboratory Quest Diagnostics Inc posted a 241% rise in second-quarter profit on Thursday, as vaccine rollouts and a drop in COVID-19 cases spurred a recovery in its core non-coronavirus testing businesses.
Quest Diagnostics Inc on Thursday reported a first-quarter profit that exceeded Wall Street expectations as a recovery in its non-COVID-19 businesses offset a slowdown in coronavirus testing.
Abbott Laboratories fell short of first-quarter revenue estimates on Tuesday due to easing demand for some of its COVID-19 tests, stoking fears of slowing growth for the business as vaccinations gain steam across the globe.
Investors will be squarely focused on Abbott Laboratories results on Tuesday to assess the impact of swift vaccination rollout on demand for the company's COVID-19 tests.
Quest Diagnostics has urged a federal judge to dismiss a former Amazon employee's claims that the lab-testing company violated Pennsylvania law by reporting his positive test for marijuana without telling Amazon he was using it for medical reasons.
Medical device maker Quest Diagnostics Inc's quarterly profit beat estimates on Thursday, boosted by robust demand for its COVID-19 testing services as coronavirus infections surged in the United States.
Quest Diagnostics Inc on Thursday posted a near 129% rise in quarterly profit on robust demand for the clinical lab operator's COVID-19 testing services.
* U.S. FDA SAYS AUTHORIZES FIRST COVID-19 AND FLU COMBINATION TEST FOR USE WITH HOME-COLLECTED SAMPLES
Quest Diagnostics Inc <DGX.N> said on Tuesday the nationwide surge in coronavirus cases has led to a slight increase in turnaround time for its COVID-19 testing.
Quest Diagnostics Inc raised its full-year earnings expectations on Thursday after a strong quarterly beat and forecast robust demand for COVID-19 tests during the fall season and into 2021.
Quest Diagnostics Inc reported a 164% rise in third-quarter profit on Thursday, as demand for tests offered by the clinical lab operator recovered on easing of COVID-19 related restrictions.
Drugmakers around the world are rushing to develop treatments for COVID-19, the respiratory disease caused by the novel coronavirus that has killed hundreds of thousands. Several companies are developing antibody treatments, similar to Regeneron Pharmaceutical Inc's treatment...
Walmart Inc said on Tuesday it would run a pilot project to deliver self-collection test kits for coronavirus through automated drones at customers' doorsteps.
Corona Capital is a column updated throughout the day by Breakingviews columnists around the world with short, sharp pandemic-related insights.
Quest Diagnostics <DGX.N> on Thursday raised its full-year revenue and profit forecast, benefiting from growing demand for its non-COVID-19 testing services.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.